报告题目：“Investigational therapies for hepatitis B and liver cancer: will anything really work?”
报告人：Timothy M. Block
Timothy M. Block, Ph.D., M.B. is President and Co-founder of the Hepatitis B Foundation; the Baruch S. Blumberg Institute; and the Pennsylvania Biotechnology Center. The Baruch S. Blumberg Institute is a nonprofit translational research organization, where Nobel Prize winning scientist Baruch S. Blumberg, worked part time, until his passing, in 2011. Dr. Block’s work with Baruch S Blumberg, Anand Mehta and Raymond Dwek, pioneered the use of glycoproteomics for detection of biomarkers of liver cancer, leading to the use of GP73 and core fucosylated serum proteins as risk stratifiers for liver cirrhosis and hepatocellular carcinoma. His work with Ying Su led to use of “microDNA” detected in the urine as a cancer marker. More recently, he and his colleagues have identified small molecule inhibitors of hepatitis B virus, which are in clinical phase human testing, today.
He is scientific co-founder of several life sciences companies, co-inventor on 20 issued patents and 23 applications, has co-authored more than 240 scholarly papers, and was named a “Visionary in Hepatitis” by the World Hepatitis Alliance in 2017. He was elected (2017) US National Academy of Inventors, awarded an honorary Doctor (1999), and is Adjunct Professor at Geisinger Commonwealth School of Medicine and the University of Pennsylvania School of Medicine.